导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.91% | 1509/4773 |
| 近一周 | -1.27% | 1926/5465 |
| 近一月 | -8.64% | 5019/5421 |
| 近一季 | -19.09% | 4863/5231 |
| 近半年 | -0.70% | 1556/4920 |
| 近一年 | 8.04% | 1389/4394 |
| 近两年 | 118.56% | 445/2954 |
| 近三年 | 71.13% | 336/2253 |
| 成立以来 | 109.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.73% 1930/4961 |
36.88% 879/5312 |
- - |
- - |
| 2025 | 51.36% 440/4813 |
-1.67% 2735/3635 |
3.22% 1108/4076 |
50.71% 295/4524 |
-1.04% 2796/4813 |
| 2024 | 14.76% 1012/3463 |
-3.72% 1550/2808 |
-6.39% 1934/3014 |
29.48% 156/3129 |
-1.66% 1786/3463 |
| 2023 | -17.74% 1758/2656 |
2.18% 1420/2280 |
-6.88% 1735/2385 |
-8.74% 1725/2515 |
-5.26% 1305/2655 |
| 2022 | -28.12% 1533/2207 |
-19.41% 1451/1919 |
5.87% 812/2016 |
-17.84% 1650/2113 |
2.53% 906/2208 |
| 2021 | 14.72% 322/1822 |
-5.76% 956/1255 |
26.73% 66/1330 |
-6.18% 904/1466 |
2.39% 606/1822 |
| 2020 | 67.72% 84/1250 |
3.60% 113/1028 |
30.27% 60/1067 |
7.70% 764/1164 |
15.39% 210/1184 |
| 2019 | 44.89% 161/1092 |
35.12% 100/754 |
-9.85% 697/804 |
7.56% 83/850 |
10.58% 117/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.20% 261/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信创业板ETF VS. 长安沪深300非周期A(740101) |